MD Anderson and Jazz Pharmaceuticals Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers
November 08, 2023
November 08, 2023
HOUSTON, Texas, Nov. 8 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.
The collaboration will combine MD Anderson's translational medicine and clinical r . . .
The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.
The collaboration will combine MD Anderson's translational medicine and clinical r . . .